671 related articles for article (PubMed ID: 16830186)
1. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.
Bhatti Z; Shaukat A; Almyroudis NG; Segal BH
Mycopathologia; 2006 Jul; 162(1):1-15. PubMed ID: 16830186
[TBL] [Abstract][Full Text] [Related]
2. Changing epidemiology of rare mould infections: implications for therapy.
Malani AN; Kauffman CA
Drugs; 2007; 67(13):1803-12. PubMed ID: 17722951
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
4. Complications of hematopoietic stem transplantation: Fungal infections.
Omrani AS; Almaghrabi RS
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):239-244. PubMed ID: 28636889
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole in the treatment of invasive mold infections in transplant recipients.
Fortún J; Martín-Dávila P; Sánchez MA; Pintado V; Alvarez ME; Sánchez-Sousa A; Moreno S
Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):408-13. PubMed ID: 12827536
[TBL] [Abstract][Full Text] [Related]
7. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.
Pagano L; Caira M; Nosari A; Van Lint MT; Candoni A; Offidani M; Aloisi T; Irrera G; Bonini A; Picardi M; Caramatti C; Invernizzi R; Mattei D; Melillo L; de Waure C; Reddiconto G; Fianchi L; Valentini CG; Girmenia C; Leone G; Aversa F
Clin Infect Dis; 2007 Nov; 45(9):1161-70. PubMed ID: 17918077
[TBL] [Abstract][Full Text] [Related]
8. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges.
Ben-Ami R; Lewis RE; Kontoyiannis DP
Curr Opin Infect Dis; 2009 Aug; 22(4):376-84. PubMed ID: 19491674
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009).
Klingspor L; Saaedi B; Ljungman P; Szakos A
Mycoses; 2015 Aug; 58(8):470-7. PubMed ID: 26152371
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.
Marr KA; Carter RA; Crippa F; Wald A; Corey L
Clin Infect Dis; 2002 Apr; 34(7):909-17. PubMed ID: 11880955
[TBL] [Abstract][Full Text] [Related]
11. Changes in the epidemiological landscape of invasive mould infections and disease.
Lass-Flörl C; Cuenca-Estrella M
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462
[TBL] [Abstract][Full Text] [Related]
12. [Current approaches to diagnosis and treatment of invasive fungal infection in HSCT recipients].
Shao Q; Shen DX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1619-23. PubMed ID: 20030960
[TBL] [Abstract][Full Text] [Related]
13. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey.
Sinkó J; Csomor J; Nikolova R; Lueff S; Kriván G; Reményi P; Bátai A; Masszi T
Transpl Infect Dis; 2008 Apr; 10(2):106-9. PubMed ID: 17605727
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
15. Patients at high risk of invasive fungal infections: when and how to treat.
Rüping MJ; Vehreschild JJ; Cornely OA
Drugs; 2008; 68(14):1941-62. PubMed ID: 18778118
[TBL] [Abstract][Full Text] [Related]
16. [The role of voriconazole in the treatment of emerging mycoses].
Pastor FJ; Guarro J
Rev Iberoam Micol; 2007 Sep; 24(3):228-32. PubMed ID: 17874861
[TBL] [Abstract][Full Text] [Related]
17. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections.
Maschmeyer G
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i27-30. PubMed ID: 19372178
[TBL] [Abstract][Full Text] [Related]
18. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
[TBL] [Abstract][Full Text] [Related]
19. [Current indications for voriconazole in onco-hematological patients].
Jarque I; Sanz MA
Rev Iberoam Micol; 2007 Sep; 24(3):213-6. PubMed ID: 17874858
[TBL] [Abstract][Full Text] [Related]
20. Mold infections in lung transplant recipients.
Bhaskaran A; Hosseini-Moghaddam SM; Rotstein C; Husain S
Semin Respir Crit Care Med; 2013 Jun; 34(3):371-9. PubMed ID: 23821511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
